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IMPACT OF TREATMENT OF OCULAR CHRONIC GVHD WITH A SCLERAL
LENS PROSTHETIC DEVICE AS A NATIONAL NETWORK OF CLINICAL CEN-
TERS EXPANDS
Jacobs, D.S.1,2, Le, H.-G.T.1, Carrasquillo, K.G.1 1Boston Foundation for
Sight, Needham, MA; 2Harvard Medical School, Boston, MA
Purpose: To study impact of Prosthetic Replacement of the Ocular
Surface Ecosystem (PROSE) treatment in patients with ocular
chronic graft-versus-host-disease (cGVHD) as clinical services ex-
pand to partner clinics based at academic tertiary eye care centers
across the United States (US).
Methods: Retrospective review of PROSE manufacturing database
from Jan 2002 through March 2011. Number of patients treated for
diagnosis of ocular cGVHD by year, gender, age, baseline NEI
VFQ-25, state of residence, and location of treatment are reported.
Baseline Composite NEI VFQ-25 score and self-reported general
health score, and changes in those scores at 6 months, in a 4-month
2010 cohort of patients frommain center and two partner clinics, are
compared by t-test.
Results: 333 patients with ocular cGVHD were treated with scleral
lens prosthetic devices from 2002 through March 2011. M:F 5
187:146. Mean age at time of treatment is 50 years613. One patient
with ocular cGVHD was treated in 2002, increasing to 78 patients
with this diagnosis treated in 2010. Percentage of patients treated
at partner clinics increased from 16% in 2009, to 33% in 2010, to
64% in the first quarter of 2011. Significant improvement in visual
function was observed in patients treated at main center in Massa-
chusetts (mean improvement 5 30pts, n 5 18 p\0.001) and in pa-
tients treated at partner clinics (mean improvement 5 41pts, n 5
6, p\0.001). There is no significant difference in baseline scores, al-
though there is trend to lower scores at partner clinics for Composite
NEI VFQ-25score, p 5 0.051.
Conclusions:There is increased utilization of PROSE treatment for
ocular cGVHD over the past decade in the US, particularly with the
establishment of partner clinics. Limited data indicates that patients
treated at partner clinics have same or lower baseline visual function
and self-reported general health status when compared to patients
treated at main center. Patients treated at partner clinics achieve sim-
ilar high level of positive impact on visual function as patients treated
at main center.443
ORAL LOADING OF TACROLIMUS AND SUB-THERAPEUTIC LEVELS ON
THE DAY OF TRANSPLANT DO NOT PREDICT THE INCIDENCE OF ACUTE
GRAFT VERSUS HOST DISEASE OR SURVIVAL AFTER ALLOGENEIC STEM
CELL TRANSPLANT
MacPherson, J.1, Bachier, C.1, LeMaistre, C.F.1, Sowell, H.2, Garcia, L.2,
Curel-Sanchez, A.2, Cain, W.2, Caga, U.2, Means, J.2, Shaughnessy, P.1
1Texas Transplant Institute, San Antonio, TX; 2Methodist Hospital,
Texas Transplant Institute, San Antonio, TX
Tacrolimus is proven to be effective in the prophylaxis of acute
graft versus host disease (aGVHD) after allogeneic stem cell trans-
plant (ASCT). Published studies that initiate tacrolimus loading in-
travenously indicate that levels should be between 5 and 20ug/L on
the day of transplant (Day 0). Our institution often performs ASCT
in the outpatient setting and therefore developed a process for oral
loading of tacrolimus. We retrospectively reviewed our experience
in 94 consecutive patients (pts) who received ASCT from 10/10
HLA matched donors; 47 were matched sibling donors (MSD) and
47 were matched unrelated donors (MUD) with a median age of
50 and 52 respectively. Preparative regimens were IV busulfan based
in 68 patients (BuFlu n5 44, BuCy n5 24), TBI based in 19 pts and
other in 7 pts. All patients received GVHD prophylaxis with tacro-
limus started orally between day -3 and -1 at a dose of 0.06mg/kg/
day divided twice daily. Standard short course methotrexate
(MTX) was prescribed for all pts (D1 dose 5 15mg/m2, D3, D6
and D11 dose5 10mg/m2). Pts who had sub-therapeutic tacrolimus
levels (less than 5ug/L on day 0 were compared to patients who had
therapeutic tacrolimus levels (greater than 5ug/L) for any incidence
of aGVHD and overall survival (OS). Sixty-nine patients had tacro-
limus levels less than 5ug/L on day 0 and 25 pts had tacrolimus levelsof 5ug/L or greater. There was no difference in the incidence of
aGVHD or survival between the groups (Table 1). Thirty-one pts
did not receive the entireMTXdose prescribed (most commonly be-
cause of withholding day 11MTX dose), but there was no significant
difference in the incidence of aGVHD in these pts despite the level of
tacrolimus on day 0. With a median follow up of 441 days, 54/94 pts
(57%) are alive; 40/69 pts (58%) had day 0 tacrolimus levels less than
5ug/L and 14/25 pts (56%) had day 0 levels greater than or equal to
5ug/L. In conclusion, oral loading of tacrolimus prior to ASCT at
our institution results in sub-therapeutic levels on the day of trans-
plant in the majority of pts; however, this does not appear to impact
incidence of aGVHDor survival. This study was limited by its retro-
spective nature, small size and single center experience. Prospective
randomized studies will be needed to determine if oral loading of ta-
crolimus impacts outcomes of ASCT.
Tacro < 5ug/L Tacro $ 5ug/L Overall
Outcome (n 5 69) (n 5 25) (n 5 94) p valueMUD OS 26.7 22.3 25.4 0.266
SIB OS 22.1 18.8 22.9 0.451
Overall OS 24.8 23.4 24.4 0.781
MUD aGVHD 19/31 (61%) 13/16 (50%) 32/47 (68%) 0.345
SIB aGVHD 15/38 (39%) 5/9 (56%) 20/47 (43%) 0.584
Overall aGVHD 34/69 (49%) 18/25 (72%) 52/94 (55%) 0.117Tacro indicates tacrolimus; OS, overall survival; MUD, matched unre-
lated donor; SIB, sibling. Survival determined in mean months from
date of transplant.444
RISK FACTORS FOR THE DEVELOPMENT OF GRAFT VERSUS HOST DIS-
EASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANPLANTATION
(allo-HSCT)
Hamilton, B.K.1, Bolwell, B.J.1, Rybicki, L.2, Kalaycio, M.1, Tench, S.1,
Hanna, R.3, Duong, H.1, Sobecks, R.1, Pohlman, B.1, Andresen, S.1,
Copelan, E.A.1 1Cleveland Clinic Taussig Cancer Institute, Cleveland,
OH; 2Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 3Cleve-
land Clinic, Cleveland, OH
Graft versus host disease (GVHD) remains a major cause of mor-
bidity and mortality in allo-HSCT. In this study, we evaluated the
correlation of acute and chronic GVHD with patient characteristics
and specific GVHD prevention regimens.
We identified 628 patients who underwent allo-HSCT from
2000-2010 at our single institution. Diagnoses included AML,
MDS, CML,MF andMPN, ALL, lymphoma and AA.We evaluated
all transplant and donor types including myeloablative (MA), re-
duced intensity (RIC); matched related donors (MRD), unrelated
donors (URD), and umbilical cord blood donors (UCB). GVHD
prophylaxis regimens included the use of methotrexate (MTX)
with tacrolimus (FK) or cyclosporine (CSA); and mycophenolate
mofetil (MMF) with FK or CSA. Stepwise Cox proportional hazards
analysis was used to identify multivariable risk factors for develop-
ment of aGVHD, cGVHD and relapse.
In multivariable analysis, three variables were identified that were
associated with an increased risk of aGVHD: transplant type, donor
type, and cell source.MA regimen vs RIC (HR 1.99, 95%CI 1.4-2.8,
p\0.001), URD transplant recipients vs MRD (HR 1.2, 95% CI
1.01-1.5, p 5 0.048), and transplant from peripheral stem cells
(PSC) vs bone marrow (BM) or UCB (HR 1.61, 95% CI 1.18-
2.19, p 5 0.002) were associated with increased risk for aGVHD.
Older age was associated with decreased risk of grade 3-4 aGVHD,
(HR 0.84, 95%CI 0.73-0.98, p5 0.024), perhaps owing to the use of
RIC regimens in older pts. There were no other statistically signifi-
cant correlations. Female gender was associated with higher risk (HR
1.3, 95% CI 1.04-1.7, p 5 0.022) of cGVHD. CSA/MTX prophy-
laxis compared to FK/MTX demonstrated an increased risk of
cGVHD, (HR 1.84, 95% CI 1.24-2.74, p 5 0.002). There was no
significant association between relapsed disease in regards to trans-
plant type, donor type, or GVHD prevention regimens. However,
PSC had an increased risk of disease relapse (HR 2.38, 95% CI
S368 Poster Session II1.04-5.58, p5 0.04) when compared with UCB, but not with BM as
cell source (p 5 0.17).
This retrospective single institutional study of 628 consecutive al-
logeneic transplantation patients revealed some novel findings. PSC
were associated with a higher incidence of aGVHD, but not
cGVHD. The combination of FK/MTXwas associated with a lower
risk of cGVHD thanCSA/MTXand will need to be investigated fur-
ther. Validation of these findings requires large cooperative prospec-
tive studies.445
TNFa -238A ALLELE IDENTIFIES PATIENTS WHO DEVELOP BOTH ACUTE
AND CHRONIC GVHD AFTER MATCHED UNRELATED DONOR TRANS-
PLANT IN CHILDREN: A PEDIATRIC BLOOD AND MARROW TRANSPLANT
CONSORTIUM STUDY
Goyal, R.K.1, Kim, Y.2, Lin, Y.2, Schultz, K.R.3, Yanik, G.4,
Ferrell, R.E.5, Fairfull, L.5, Atlas, M.6 1Children’s Hospital of Pittsburgh
of UPMC, Pittsburgh, PA; 2University of Pittsburgh, Pittsburgh, PA;
3University of British Columbia, British Columbia, BC, Canada; 4Uni-
versity ofMichigan Comprehensive Cancer Center, Ann Arbor,MI; 5Uni-
versity of Pittsburgh, Pittsburgh, PA; 6Schneider Children’s
Hospital/Albert Einstein College of Medicine, New York, NY
Introduction: The inflammatory cytokine tumor necrosis factor-
a (TNFa) plays a central role in the pathogenesis of acute GVHD,
but its role in chronic GVHD is less clearly defined.We recently de-
scribed an association between the recipient TNFa gene polymor-
phisms and the severity of acute GVHD in pediatric unrelated
donor BMT (Goyal et al, Biol Blood Marrow Transplant, 2010). We
now report the correlative analyses between the recipient and donor
TNFa promoter region single nucleotide gene polymorphisms
(SNP) and the risk of acute and chronic GVHD in this cohort.
Materials and Methods: Genotyping was performed on pretrans-
plant genomic DNA samples from recipient-donor pairs (n 5
180). To address the confounding effect of population stratification,
significant associations were reanalyzed in white recipient-donor
pairs.
Results: Twenty-three patients died before day+100; 78/153 (51%)
of the remaining evaluable patients developed cGVHD with exten-
sive disease in 60/76 (79%) patients. Similar to findings in recipients,
the donor TNFa variant A allele of -863C/A SNP (HR 3.67, p 5
0.01) and the variant C allele of -1031T/C SNP (HR 2.85, p 5
0.05) were also associated with grade III-IV aGvHD. The recipient
TNFa variant A allele of - 238G/A SNP was associated with grade
II-IV aGVHD (HR 2.38; p\0.01, previously reported) as well
with cGVHD (RR 1.68; P 5 0.02). Six out of 44 (14%) patients
(14%) with variant -238A allele compare to 40/99 (40%) patients
without -238A allele did not develop acute or chronic GVHD.
The rates of only acute (16%, 18%) and only chronic GVHD
(18%, 19%) were similar in those with or without recipient -238A al-
lele, respectively. However, 23/44 (52%) patients with the -238A al-
lele developed both acute and chronic GVHD compared with 22/99
(22%) without the -238A allele (RR 2.35, p\0.01, Table 1). These
associations remained significant when analyzed in white-only re-
cipient-donor pairs. No statistically significant association was de-
tected between the donorTNFa gene polymorphisms and the risk of
cGVHD.
Table 1.
Recipient No Acute Only Only BothTNF alpha
-238 G>Aor Chronic
GVHDAcute
GVHDChronic
GVHDAcute & Chronic
GVHD P-ValueAA/AG 6/14 (14%) 7/44 (16%) 8/44 (18%) 23/44 (52%) <0.01GG 40/99 (40%) 18/99 (19%) 19/99 (19%) 22/99 (22%)Conclusions: In this large cohort of pediatricmatched unrelated do-
nor transplants: 1) The recipient and donor TNFa -863A allele and
-1031C allele are associated with grade III-IV aGvHD. 2) The recip-
ient TNFa -238A allele identifies a subset of patients who develop
both acute and chronicGVHD.These findings deserve further studyin independent cohorts and may be clinically relevant in a risk-ad-
justed approach toGVHDmanagement in pediatric unrelated donor
transplants.446
COMPARISON OF SIROLIMUS AND MYCOPHENOLATE MOFETIL AS SAL-
VAGE TREATMENT FOR ACUTE GRAFT-VERSUS-HOST DISEASE
Nishihori, T.1, Pidala, J.1, Kim, J.2, Tomblyn,M.1, Anasetti, C.1 1Moffitt
Cancer Center, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL
Glucocorticoid refractory acute GVHD (aGVHD) is a major
source of mortality following allogeneic HCT. Comparative studies
to evaluate the efficacy of salvage immune suppressive agents are
lacking. We retrospectively compared the efficacy of sirolimus
(SIR) and mycophenolate mofetil (MMF) as salvage aGVHD ther-
apy for glucocorticoid refractory, dependent or intolerant patients.
Of 281 consecutive patients who received allogeneic HCT from
07/2004 to 09/2009, we identified 84 patients who received tacroli-
mus/methotrexate (Tac/MTX) GVHD prophylaxis, were treated
with glucocorticoids for grades 2-4 aGVHD, were refractory (n 5
72) or dependent (n 5 12) to glucocorticoids, and received 2nd
line GVHD treatment with MMF (n5 56) or SIR (n5 28). Demo-
graphics and treatment variables were similar except for year of
transplant (earlier for MMF). Disease diagnoses included AML (n
5 27), NHL (n 5 14), MDS (n 5 12), ALL (n 5 9), CML (n 5
7), CLL (n 5 4), SAA (n 5 2), MPD (n 5 5), MM/PCL (n 5 3),
and HL (n 5 1). Conditioning regimens were busulfan/fludarabine
for 71, and other regimens for 13. Except for 1 bone marrow graft
in each group, all received peripheral blood stem cells. Graft sources
were from HLA-matched siblings (35), or 8/8 HLA-matched unre-
lated donors (49). Overall grade distribution of aGVHD at time of
salvage for MMF vs. SIR was the following: grade 1 (13 vs. 2), grade
2 (31 vs. 16), grade 3 (9 vs. 5) and grade 4 (3 vs. 5). Median steroid
dose at the time of salvage was 1 (range 0.17 – 2.28) mg/kg for
MMF group and 1 (range 0.12 – 2.0) mg/kg for SIR group. Median
time from steroid to salvage was 20 (range 1 – 208) days for MMF
and 19 (range 1 – 275) days for SIR (p 5 0.84). Complete response
(CR) rates following initiation of MMF or SIR did not significantly
differ at the following time points: 1 week (MMF 30%, SIR 21%), 4
weeks (MMF 44%, SIR 46%), and 6 weeks (MMF 60%, SIR 58%).
Overall response rates (ORR) also did not differ significantly: 1 week
(MMF 57%, SIR 42%), 4 weeks (MMF 57%, SIR 77%), and 6 weeks
(MMF 72%, SIR 75%). Flare or progression of aGVHD while on
salvage regimen was noted in 50% (MMF) and 36% (SIR) of patients
(p5 0.64). Median overall survival from the time of salvage therapy
forMMF vs. SIR did not significantly differ, 11.6 (95%CI 7.0 – 28.1)
vs. 9.7 (95% CI 5.4 – 15.9) months, log-rank p5 0.88. These retro-
spective data suggest that MMF and SIR have comparable activity in
the treatment of steroid refractory or dependent acute GVHD.447
HUMAN MULTIPOTENT ADULT PROGENITOR CELLS EFFECTIVELY MOD-
ULATE ALLOREACTIVITY AFTER BONEMARROWTRANSPLANTATION RE-
DUCING GVHD WHILE PRESERVING GRAFT-VERSUS-LEUKEMIA
ACTIVITY
Metheny, L.L.1, Eid, S.3, Keller, M.3, Van Devort, A.2, Lee, Z.H.4,
Wilson, D.4, Auletta, J.2, Vant Hof, W.5, Paez, C.2, Cooke, K.R.2
1Case Western Reserve University, Cleveland, OH; 2University Hospitals
of Cleveland, Cleveland, OH; 3Case Western Reserve University, Cleve-
land, OH; 4National Center for Stem Cell and Regenerative Medicine,
Cleveland, OH; 5Athersys, Inc, Cleveland, OH
Graft-versus-host disease (GVHD) limits successful outcomes fol-
lowing allogeneic BMT (allo-BMT). The pathophysiology of
GVHD involves three distinct phases which contribute to inflamma-
tory cytokine dysregulation, the generation of cellular effectors, and
target organ injury. This framework uncovers opportunities to reg-
ulate GVHD. We examined whether reported immunosuppressive
and regenerative properties of human, bone marrow-derived
multi-potent, adult progenitor cells (hMAPCs) could regulate
GVHD using established murine models. The immuno-regulatory
